Pre-heparin lipoprotein lipase mass.

Abstract

Lipoprotein lipase (LPL) is a lipolytic enzyme involved in catalyzing the hydrolysis of triglycerides (TG) in chylomicrons and very low-density lipoprotein (VLDL) particles. Over the last decade, the clinical significance of measuring LPL mass without heparin injection has been increasingly studied. In earlier studies, it was shown that this marker was utilized to classify type 1 hyperlipoproteinemia, which is an extremely rare metabolic disorder. Later, researchers paid more attention to the clinical significance of measuring this parameter in more common metabolic disorders. Studies have shown that pre-heparin plasma LPL mass has significant relationships with serum lipid and lipoproteins, visceral fat area, and even a marker for acute inflammation, although this might be a metabolic surrogate marker which does not appear to be involved in catalyzing the hydrolysis of TG in TG-rich lipoproteins. We suggest that pre-heparin LPL mass in plasma or sera provides us with useful and important information on the pathophysiology of metabolic disorders or acute inflammation despite its simplicity from a practical point of view.

• Authors: Junji Kobayashi
• Journal: Journal of atherosclerosis and thrombosis (J Atheroscler Thromb) Vol. 11 Issue 1 Pg. 1-5 ( 2004) ISSN: 1340-3478 [Print] Japan
• PMID: 15067192 (Publication Type: Journal Article, Review)

Chemical References

• Anticoagulants
• Lipoproteins
• Heparin
• Lipoprotein Lipase

Topics

• Adipose Tissue (metabolism)
• Anticoagulants (pharmacology)
• Clinical Trials as Topic
• Heparin (pharmacology)
• Humans
• Hyperlipoproteinemias (metabolism, physiopathology)
• Lipoprotein Lipase (blood, metabolism)
• Lipoproteins (metabolism)